<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01550341</url>
  </required_header>
  <id_info>
    <org_study_id>1011007631</org_study_id>
    <secondary_id>R01DA030768</secondary_id>
    <nct_id>NCT01550341</nct_id>
  </id_info>
  <brief_title>HIV, Buprenorphine, and the Criminal Justice System</brief_title>
  <acronym>STRIDE</acronym>
  <official_title>HIV, Buprenorphine, and the Criminal Justice System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>George Mason University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Howard University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of STRIDE were changed as of July, 2014. The revised project, called STRIDE2, has a
      longitudinal, non-randomized, observational study design. The population under study consists
      of individuals living with HIV who are dependent on opioids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Presented in the results section are the summary of outcomes from the STRIDE RCT that were
      collected prior to the change in study design. The STRIDE study became STRIDE2 (NCT03583138).
      Those individuals originally enrolled in the STRIDE RCT will be followed for 12 months.

      STRIDE2 will assist in identifying and monitoring individuals' HIV risk behaviors and provide
      resources to seek treatment for their HIV care and substance use. The goal of STRIDE2 is to
      examine if there are differences in HIV, drug use, and other outcomes between individuals
      receiving treatment versus individuals actively using, not actively using and not in
      treatment, and individuals on Methadone, Suboxone, or in some other treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 23, 2012</start_date>
  <completion_date type="Actual">November 30, 2016</completion_date>
  <primary_completion_date type="Actual">November 30, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD4 Count Absolute</measure>
    <time_frame>Baseline</time_frame>
    <description>CD4 Count Absolute</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4 Count Absolute</measure>
    <time_frame>6 Months</time_frame>
    <description>CD4 Count Absolute</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4 Count Absolute</measure>
    <time_frame>12 Months</time_frame>
    <description>CD4 Count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4 Percent</measure>
    <time_frame>Baseline</time_frame>
    <description>CD4 Percent</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4 Percent</measure>
    <time_frame>6 Months</time_frame>
    <description>CD4 Percent</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4 Percent</measure>
    <time_frame>12 Months</time_frame>
    <description>CD4 Percent</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral Load</measure>
    <time_frame>Baseline</time_frame>
    <description>Viral Load</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral Load</measure>
    <time_frame>6 Months</time_frame>
    <description>Viral Load</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral Load</measure>
    <time_frame>12 Months</time_frame>
    <description>Viral Load</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Log Viral Load</measure>
    <time_frame>Baseline</time_frame>
    <description>Log Viral Load</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Log Viral Load</measure>
    <time_frame>6 Months</time_frame>
    <description>Log Viral Load</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Log Viral Load</measure>
    <time_frame>12 Months</time_frame>
    <description>Log Viral Load</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improved Opioid Treatment Outcomes</measure>
    <time_frame>baseline, 3 months, 9 months, 12 months</time_frame>
    <description>Monitor relapse to opioid use, retention on Buprenorphine or placebo, percent days using opioids, lower addiction severity, lower craving, between baseline and subsequent follow-up visits. Monitor urine toxicology screens on every visit for approximately one year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improved Criminal Justice Outcomes</measure>
    <time_frame>baseline, wk 4, 9, 13, 18, 22, 27, 31, 36, 40, 45, 49, 52</time_frame>
    <description>Measure change in time to reincarceration,number of days reincarcerated, and crime days, between baseline and each monthly follow-up visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <condition>Acquired Immunodeficiency Syndrome</condition>
  <condition>Opiate Addiction</condition>
  <condition>Drug Dependence</condition>
  <arm_group>
    <arm_group_label>Buprenorphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine/naloxone</intervention_name>
    <description>2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
    <arm_group_label>Buprenorphine</arm_group_label>
    <other_name>Suboxone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV+

          -  Age ≥18 yrs

          -  Meets DSM-IV criteria for opioid dependence

          -  Has medical entitlements in DC

          -  Able to provide informed consent

          -  Able to communicate in English or Spanish

        Exclusion Criteria:

          -  Being prescribed an opiate medication for a chronic pain condition or expressing the
             need to be placed on chronic pain medical conditions for a documented pain condition

          -  Currently receiving methadone dosing of over 30 mg per day and uninterested in
             changing to buprenorphine

          -  AST and ALT &gt;5x the upper limit of normal (AST≥175, ALT≥195)

          -  Pregnant or unwilling to use contraception (including OCPs, patch, Depo-Provera,
             condoms, etc.)

          -  Breastfeeding or unwilling to stop breastfeeding

          -  Subject is part of another pharmacological research study

          -  Liver dysfunction (acute hepatitis, liver failure or hepatic dysfunction)

          -  Suicidal ideation

          -  Hypersensitivity to buprenorphine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederick Altice, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University School of Medicine/AIDS Program</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Faye Taxman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>George Mason University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Lawson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Howard University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Howard University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 21, 2011</study_first_submitted>
  <study_first_submitted_qc>March 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2012</study_first_posted>
  <results_first_submitted>August 17, 2017</results_first_submitted>
  <results_first_submitted_qc>April 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 6, 2020</results_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>AIDS</keyword>
  <keyword>Opiate Addiction</keyword>
  <keyword>Drug Dependence</keyword>
  <keyword>Buprenorphine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Behavior, Addictive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Buprenorphine</title>
          <description>Buprenorphine/naloxone: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo Oral Tablet: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Buprenorphine</title>
          <description>Buprenorphine/naloxone: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo Oral Tablet: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.29" spread="6.54"/>
                    <measurement group_id="B2" value="55.59" spread="5.26"/>
                    <measurement group_id="B3" value="52.81" spread="6.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>CD4 Count Absolute</title>
        <description>CD4 Count Absolute</description>
        <time_frame>Baseline</time_frame>
        <population>Participants with complete lab results.</population>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Buprenorphine/naloxone: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral Tablet: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Count Absolute</title>
          <description>CD4 Count Absolute</description>
          <population>Participants with complete lab results.</population>
          <units>cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="486.15" spread="308.34"/>
                    <measurement group_id="O2" value="403.92" spread="233.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CD4 Count Absolute</title>
        <description>CD4 Count Absolute</description>
        <time_frame>6 Months</time_frame>
        <population>Participants with complete lab results.</population>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Buprenorphine/naloxone: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral Tablet: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Count Absolute</title>
          <description>CD4 Count Absolute</description>
          <population>Participants with complete lab results.</population>
          <units>cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="455.52" spread="289.74"/>
                    <measurement group_id="O2" value="551.23" spread="82.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CD4 Count Absolute</title>
        <description>CD4 Count</description>
        <time_frame>12 Months</time_frame>
        <population>Participants with complete lab results.</population>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Buprenorphine/naloxone: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral Tablet: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Count Absolute</title>
          <description>CD4 Count</description>
          <population>Participants with complete lab results.</population>
          <units>cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="490.25" spread="298.65"/>
                    <measurement group_id="O2" value="492.33" spread="260.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CD4 Percent</title>
        <description>CD4 Percent</description>
        <time_frame>Baseline</time_frame>
        <population>Participants with complete lab results.</population>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Buprenorphine/naloxone: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral Tablet: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Percent</title>
          <description>CD4 Percent</description>
          <population>Participants with complete lab results.</population>
          <units>CD4 Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.36" spread="8.56"/>
                    <measurement group_id="O2" value="25.7" spread="12.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CD4 Percent</title>
        <description>CD4 Percent</description>
        <time_frame>6 Months</time_frame>
        <population>Participants with complete lab results.</population>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Buprenorphine/naloxone: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral Tablet: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Percent</title>
          <description>CD4 Percent</description>
          <population>Participants with complete lab results.</population>
          <units>CD4 Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.33" spread="1.88"/>
                    <measurement group_id="O2" value="28.56" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CD4 Percent</title>
        <description>CD4 Percent</description>
        <time_frame>12 Months</time_frame>
        <population>Participants with complete lab results.</population>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Buprenorphine/naloxone: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral Tablet: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Percent</title>
          <description>CD4 Percent</description>
          <population>Participants with complete lab results.</population>
          <units>CD4 Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.14" spread="9.6"/>
                    <measurement group_id="O2" value="27.95" spread="12.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Viral Load</title>
        <description>Viral Load</description>
        <time_frame>Baseline</time_frame>
        <population>Participants with complete lab results.</population>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Buprenorphine/naloxone: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral Tablet: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load</title>
          <description>Viral Load</description>
          <population>Participants with complete lab results.</population>
          <units>IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1465.00" spread="551.17"/>
                    <measurement group_id="O2" value="896.50" spread="1569.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Viral Load</title>
        <description>Viral Load</description>
        <time_frame>6 Months</time_frame>
        <population>Participants with complete lab results.</population>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Buprenorphine/naloxone: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral Tablet: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load</title>
          <description>Viral Load</description>
          <population>Participants with complete lab results.</population>
          <units>IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9269.04" spread="4778.9"/>
                    <measurement group_id="O2" value="7891.08" spread="26598.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Viral Load</title>
        <description>Viral Load</description>
        <time_frame>12 Months</time_frame>
        <population>Participants with complete lab results.</population>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Buprenorphine/naloxone: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral Tablet: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load</title>
          <description>Viral Load</description>
          <population>Participants with complete lab results.</population>
          <units>IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8122.10" spread="18268.77"/>
                    <measurement group_id="O2" value="19425.71" spread="51342.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Log Viral Load</title>
        <description>Log Viral Load</description>
        <time_frame>Baseline</time_frame>
        <population>Participants with complete lab results.</population>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Buprenorphine/naloxone: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral Tablet: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Log Viral Load</title>
          <description>Log Viral Load</description>
          <population>Participants with complete lab results.</population>
          <units>log(IU/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" spread="1.02"/>
                    <measurement group_id="O2" value="2.00" spread=".97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Log Viral Load</title>
        <description>Log Viral Load</description>
        <time_frame>6 Months</time_frame>
        <population>Participants with complete lab results.</population>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Buprenorphine/naloxone: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral Tablet: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Log Viral Load</title>
          <description>Log Viral Load</description>
          <population>Participants with complete lab results.</population>
          <units>log(IU/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22" spread="1.35"/>
                    <measurement group_id="O2" value="1.79" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Log Viral Load</title>
        <description>Log Viral Load</description>
        <time_frame>12 Months</time_frame>
        <population>Participants with complete lab results.</population>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Buprenorphine/naloxone: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral Tablet: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Log Viral Load</title>
          <description>Log Viral Load</description>
          <population>Participants with complete lab results.</population>
          <units>log(IU/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.40" spread="1.33"/>
                    <measurement group_id="O2" value="1.84" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improved Opioid Treatment Outcomes</title>
        <description>Monitor relapse to opioid use, retention on Buprenorphine or placebo, percent days using opioids, lower addiction severity, lower craving, between baseline and subsequent follow-up visits. Monitor urine toxicology screens on every visit for approximately one year.</description>
        <time_frame>baseline, 3 months, 9 months, 12 months</time_frame>
        <population>This outcome was not collected and analyzed due to the change in study design (see study description).</population>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Buprenorphine/naloxone: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral Tablet: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Improved Opioid Treatment Outcomes</title>
          <description>Monitor relapse to opioid use, retention on Buprenorphine or placebo, percent days using opioids, lower addiction severity, lower craving, between baseline and subsequent follow-up visits. Monitor urine toxicology screens on every visit for approximately one year.</description>
          <population>This outcome was not collected and analyzed due to the change in study design (see study description).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improved Criminal Justice Outcomes</title>
        <description>Measure change in time to reincarceration,number of days reincarcerated, and crime days, between baseline and each monthly follow-up visit.</description>
        <time_frame>baseline, wk 4, 9, 13, 18, 22, 27, 31, 36, 40, 45, 49, 52</time_frame>
        <population>These data were never collected and summarized due to the change in study design (see study description).</population>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Buprenorphine/naloxone: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral Tablet: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Improved Criminal Justice Outcomes</title>
          <description>Measure change in time to reincarceration,number of days reincarcerated, and crime days, between baseline and each monthly follow-up visit.</description>
          <population>These data were never collected and summarized due to the change in study design (see study description).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="00000"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Buprenorphine</title>
          <description>Buprenorphine/naloxone: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo Oral Tablet: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Frederick Altice, Principal Investigator</name_or_title>
      <organization>Yale University</organization>
      <phone>203-737-2883</phone>
      <email>frederick.altice@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

